B-intervention	0	4	Oral
I-intervention	5	16	ibandronate
O	17	24	reduces
O	25	28	the
O	29	33	risk
O	34	36	of
B-condition	37	45	skeletal
I-condition	46	59	complications
O	60	62	in
O	63	69	breast
O	70	76	cancer
O	77	85	patients
O	86	90	with
O	91	101	metastatic
O	102	106	bone
O	107	114	disease
O	114	115	:
O	116	123	results
O	124	128	from
O	129	132	two
O	133	143	randomised
O	143	144	,
O	145	152	placebo
O	152	153	-
O	153	163	controlled
O	164	169	phase
O	170	173	III
O	174	181	studies
O	181	182	.

O	183	191	Although
O	192	203	intravenous
O	204	205	(
O	205	206	i
O	206	207	.
O	208	209	v
O	209	210	.
O	210	211	)
O	212	227	bisphosphonates
O	228	231	are
O	232	235	the
O	236	244	standard
O	245	247	of
O	248	252	care
O	253	256	for
O	257	267	metastatic
O	268	272	bone
O	273	280	disease
O	280	281	,
O	282	286	they
O	287	290	are
O	291	295	less
O	296	300	than
O	301	306	ideal
O	307	310	for
O	311	315	many
O	316	324	patients
O	325	328	due
O	329	331	to
O	332	340	infusion
O	340	341	-
O	341	348	related
O	349	356	adverse
O	357	363	events
O	364	365	(
O	365	368	AEs
O	368	369	)
O	369	370	,
O	371	373	an
O	374	383	increased
O	384	388	risk
O	389	391	of
O	392	397	renal
O	398	406	toxicity
O	407	410	and
O	411	414	the
O	415	428	inconvenience
O	429	431	of
O	432	439	regular
O	440	448	hospital
O	449	455	visits
O	455	456	.

O	457	460	The
O	461	464	use
O	465	467	of
O	468	472	oral
O	473	487	bisphosphonate
O	488	495	therapy
O	496	498	is
O	499	506	limited
O	507	509	by
O	510	518	concerns
O	519	523	over
O	524	532	efficacy
O	533	536	and
O	537	553	gastrointestinal
O	554	555	(
O	555	557	GI
O	557	558	)
O	559	563	side
O	564	571	effects
O	571	572	.

O	573	578	There
O	579	586	remains
O	587	588	a
O	589	597	clinical
O	598	602	need
O	603	606	for
O	607	609	an
O	610	614	oral
O	615	629	bisphosphonate
O	630	634	that
O	635	641	offers
O	642	652	equivalent
O	653	661	efficacy
O	662	664	to
O	665	666	i
O	666	667	.
O	668	669	v
O	669	670	.
O	671	686	bisphosphonates
O	686	687	,
O	688	692	good
O	693	705	tolerability
O	706	709	and
O	710	716	dosing
O	717	728	convenience
O	728	729	.

O	730	734	Oral
O	735	746	ibandronate
O	746	747	,
O	748	749	a
O	750	756	highly
O	757	763	potent
O	763	764	,
O	765	770	third
O	770	771	-
O	771	781	generation
O	782	801	aminobisphosphonate
O	801	802	,
O	803	806	has
O	807	811	been
O	812	821	evaluated
O	822	824	in
O	825	830	phase
O	831	834	III
O	835	843	clinical
O	844	850	trials
O	851	853	of
O	854	862	patients
O	863	867	with
O	868	872	bone
O	873	883	metastases
O	884	888	from
O	889	895	breast
O	896	902	cancer
O	902	903	.

O	904	906	In
O	907	910	two
O	911	917	pooled
O	918	923	phase
O	924	927	III
O	928	935	studies
O	935	936	,
B-eligibility	937	945	patients
I-eligibility	946	950	with
I-eligibility	951	957	breast
I-eligibility	958	964	cancer
I-eligibility	965	968	and
I-eligibility	969	973	bone
I-eligibility	974	984	metastases
O	985	989	were
O	990	1000	randomised
O	1001	1003	to
O	1004	1011	receive
O	1012	1016	oral
O	1017	1028	ibandronate
O	1029	1031	50
O	1032	1034	mg
O	1035	1036	(
O	1036	1037	n
O	1037	1038	=
B-intervention-participants	1038	1041	287
O	1041	1042	)
O	1043	1045	or
B-control	1046	1053	placebo
O	1054	1055	(
O	1055	1056	n
O	1056	1057	=
B-control-participants	1057	1060	277
O	1060	1061	)
O	1062	1066	once
O	1067	1072	daily
O	1073	1076	for
O	1077	1079	up
O	1080	1082	to
O	1083	1085	96
O	1086	1091	weeks
O	1091	1092	.

O	1093	1096	The
O	1097	1104	primary
O	1105	1108	end
O	1109	1114	point
O	1115	1118	was
O	1119	1122	the
B-outcome-Measure	1123	1131	skeletal
I-outcome-Measure	1132	1141	morbidity
I-outcome-Measure	1142	1148	period
I-outcome-Measure	1149	1153	rate
I-outcome-Measure	1154	1155	(
I-outcome-Measure	1155	1159	SMPR
I-outcome-Measure	1159	1160	)
O	1160	1161	,
O	1162	1169	defined
O	1170	1172	as
O	1173	1176	the
O	1177	1183	number
O	1184	1186	of
O	1187	1189	12
O	1189	1190	-
O	1190	1194	week
O	1195	1202	periods
O	1203	1207	with
O	1208	1211	new
O	1212	1220	skeletal
O	1221	1234	complications
O	1234	1235	.

O	1236	1248	Multivariate
O	1249	1256	Poisson
O	1256	1257	'
O	1257	1258	s
O	1259	1269	regression
O	1270	1278	analysis
O	1279	1282	was
O	1283	1287	used
O	1288	1290	to
O	1291	1297	assess
O	1298	1301	the
O	1302	1310	relative
O	1311	1315	risk
O	1316	1318	of
O	1319	1327	skeletal
O	1327	1328	-
O	1328	1335	related
O	1336	1342	events
O	1343	1345	in
O	1346	1350	each
O	1351	1360	treatment
O	1361	1366	group
O	1367	1373	during
O	1374	1377	the
O	1378	1383	study
O	1384	1390	period
O	1390	1391	.

O	1392	1396	Oral
O	1397	1408	ibandronate
O	1409	1411	50
O	1412	1414	mg
O	1415	1428	significantly
O	1429	1436	reduced
O	1437	1440	the
B-outcome	1441	1445	mean
I-outcome	1446	1450	SMPR
O	1451	1459	compared
O	1460	1464	with
O	1465	1472	placebo
O	1473	1474	(
B-iv-cont-mean	1474	1475	0
I-iv-cont-mean	1475	1476	.
I-iv-cont-mean	1476	1478	95
O	1479	1481	vs
B-cv-cont-mean	1482	1483	1
I-cv-cont-mean	1483	1484	.
I-cv-cont-mean	1484	1486	18
O	1486	1487	,
O	1488	1489	P
O	1489	1490	=
O	1490	1491	0
O	1491	1492	.
O	1492	1495	004
O	1495	1496	)
O	1496	1497	.

O	1498	1503	There
O	1504	1507	was
O	1508	1509	a
O	1510	1521	significant
O	1522	1531	reduction
O	1532	1534	in
O	1535	1538	the
B-outcome	1539	1543	mean
I-outcome	1544	1550	number
I-outcome	1551	1553	of
I-outcome	1554	1560	events
I-outcome	1561	1570	requiring
I-outcome	1571	1583	radiotherapy
O	1584	1585	(
B-iv-cont-mean	1585	1586	0
I-iv-cont-mean	1586	1587	.
I-iv-cont-mean	1587	1589	73
O	1590	1592	vs
B-cv-cont-mean	1593	1594	0
I-cv-cont-mean	1594	1595	.
I-cv-cont-mean	1595	1597	98
O	1597	1598	,
O	1599	1600	P
O	1600	1601	<
O	1601	1602	0
O	1602	1603	.
O	1603	1606	001
O	1606	1607	)
O	1608	1611	and
B-outcome	1612	1618	events
I-outcome	1619	1628	requiring
I-outcome	1629	1636	surgery
O	1637	1638	(
B-iv-cont-mean	1638	1639	0
I-iv-cont-mean	1639	1640	.
I-iv-cont-mean	1640	1642	47
O	1643	1645	vs
B-cv-cont-mean	1646	1647	0
I-cv-cont-mean	1647	1648	.
I-cv-cont-mean	1648	1650	53
O	1650	1651	,
O	1652	1653	P
O	1653	1654	=
O	1654	1655	0
O	1655	1656	.
O	1656	1659	037
O	1659	1660	)
O	1660	1661	.

O	1662	1669	Poisson
O	1669	1670	'
O	1670	1671	s
O	1672	1682	regression
O	1683	1691	analysis
O	1692	1701	confirmed
O	1702	1706	that
O	1707	1711	oral
O	1712	1723	ibandronate
O	1724	1737	significantly
O	1738	1745	reduced
O	1746	1749	the
B-outcome	1750	1754	risk
I-outcome	1755	1757	of
I-outcome	1758	1759	a
I-outcome	1760	1768	skeletal
I-outcome	1769	1774	event
O	1775	1783	compared
O	1784	1788	with
O	1789	1796	placebo
O	1797	1798	(
O	1798	1804	hazard
O	1805	1810	ratio
O	1811	1812	0
O	1812	1813	.
O	1813	1815	62
O	1815	1816	,
O	1817	1819	95
O	1819	1820	%
O	1821	1823	CI
O	1823	1824	=
O	1824	1825	0
O	1825	1826	.
O	1826	1828	48
O	1828	1829	,
O	1830	1831	0
O	1831	1832	.
O	1832	1834	79
O	1834	1835	;
O	1836	1837	P
O	1837	1838	=
O	1838	1839	0
O	1839	1840	.
O	1840	1844	0001
O	1844	1845	)
O	1845	1846	.

O	1847	1850	The
O	1851	1860	incidence
O	1861	1863	of
O	1864	1868	mild
O	1869	1878	treatment
O	1878	1879	-
O	1879	1886	related
B-outcome	1887	1892	upper
I-outcome	1893	1895	GI
I-outcome	1896	1899	AEs
O	1900	1903	was
O	1904	1912	slightly
O	1913	1919	higher
O	1920	1922	in
O	1923	1926	the
O	1927	1931	oral
O	1932	1943	ibandronate
O	1944	1946	50
O	1947	1949	mg
O	1950	1955	group
O	1956	1964	compared
O	1965	1969	with
O	1970	1977	placebo
O	1977	1978	,
O	1979	1982	but
O	1983	1987	very
O	1988	1991	few
O	1992	1999	serious
O	2000	2004	drug
O	2004	2005	-
O	2005	2012	related
O	2013	2016	AEs
O	2017	2021	were
O	2022	2030	reported
O	2030	2031	.

O	2032	2036	Oral
O	2037	2048	ibandronate
O	2049	2051	50
O	2052	2054	mg
O	2055	2057	is
O	2058	2060	an
O	2061	2070	effective
O	2070	2071	,
O	2072	2076	well
O	2076	2077	-
O	2077	2086	tolerated
O	2087	2090	and
O	2091	2101	convenient
O	2102	2111	treatment
O	2112	2115	for
O	2116	2119	the
O	2120	2130	prevention
O	2131	2133	of
O	2134	2142	skeletal
O	2143	2156	complications
O	2157	2159	of
O	2160	2170	metastatic
O	2171	2175	bone
O	2176	2183	disease
O	2183	2184	.
